Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiation
Raymond James analyst Thomas Deal initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Market Perform rating.
Raymond James analyst Thomas Deal initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Market Perform rating.